Endocyte, Inc. (ECYT)

Trade ECYT now with
12/20/2018 9:32:36 AM Endocyte Stockholders Approve Merger Agreement With Novartis
11/19/2018 6:32:21 AM Wedbush Is Raising Endocyte, Inc. (ECYT) FY19 Estimate To -0.76 From -0.77
11/19/2018 6:31:54 AM Wedbush Is Raising Endocyte, Inc. (ECYT) Q1 19 Estimate To -0.18 From -0.19
11/19/2018 6:31:31 AM Wedbush Is Raising Endocyte, Inc. (ECYT) FY18 Estimate To -0.67 From -0.69
11/19/2018 6:31:17 AM Wedbush Is Raising Endocyte, Inc. (ECYT) Q4 18 Estimate To -0.17 From -0.18
10/18/2018 2:16:42 PM Wedbush Cuts Endocyte, Inc. (ECYT) To Neutral From Outperform With $24 Down From $25 Price Target
9/14/2018 4:11:08 PM Endocyte Announces Closing Of Public Offering Of Common Stock
9/11/2018 9:33:43 PM Endocyte Prices Underwritten Registered Public Offering Of 9.46 Mln Shares At $18.50/shr
9/10/2018 8:04:40 AM Endocyte Announces FDA Acceptance Of RPFS As Alternative Primary Endpoint Of The VISION Trial
7/31/2018 8:13:10 AM Endocyte Q2 Net Loss $11.6 Mln Or $0.17/Shr Vs Loss $11.7 Mln Or $0.28/Shr Last Year
7/9/2018 9:28:01 AM Endocyte, ITM Announce Long-Term Supply Agreement For No-Carrier-Added Lutetium-177
6/22/2018 8:03:31 AM Endocyte Says Multiple Presentations Related To Endocyte’s PSMA-617 Radioligand Therapy Will Be Presented At SNMMI
6/5/2018 8:05:35 AM Endocyte Announces Enrollment Of First Patient In Phase 3 VISION Trial Of 177Lu-PSMA-617 In Prostate Cancer